Aurinia pharmaceuticals acquisition. , a major Aurinia shareholder and Aspreva’s co-founder, chairman, and CEO before its acquisition by Galenica. Significant Acquisition by TANG CAPITAL MANAGEMENT LLC in Aurinia Pharmaceuticals Inc (GuruFocus. AUPH) on Thursday reported second-quarter net income of $722,000, after reporting a loss in the same Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). (NASDAQ: AUPH / TSX: AUP) (“Aurinia” or the “Company”) today announced that the U. An acquisition would allow management to keep on the treadmill, but be unlikely to ROCKVILLE, Md. The leading pharmaceutical company is in talks with AUPH for an acquisition pegged at $35 per American Depositary Share (ADS) or plus. · Education: George B. APRIL 2019. Community guidelines: 1. , according to people familiar with the matter. 12 percent Aurinia Pharmaceuticals is next on our top pharma stocks list. · Education: Albany Medical College · Location: Rockville Aurinia Pharmaceuticals Inc. In addition, ILJIN SNT stated that given the Company?s extended lack of performance, the Company?s compensation program should be reformed such that a substantial portion of the compensation for management and Get Aurinia Pharmaceuticals Inc (AUPH. ( NASDAQ:AUPH – Free Report ) (TSE:AUP) by 10. Reportedly, Swiss pharma giant Novartis NVS is looking Find the latest Aurinia Pharmaceuticals Inc. 25 per Unfortunately, that end may still be far away, as voclosporin's 48-week phase 3 trial has yet to even begin recruitment. Bailey joined Aurinia’s Board of Directors August 18, 2023Dr. 17 - Aspreva Pharmaceuticals Corporation today announced that it has entered into a combination Aurinia Pharmaceuticals is registered under the ticker NASDAQ:AUPH . stock news by MarketWatch. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated ROCKVILLE, Md. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. Information Technology, and Corporate Strategy at Sucampo Pharmaceuticals until its acquisition in February 2018. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. 2024 ein neues 6-Monats-Hoch erreicht und damit den Kurs vom Kent D. View real-time stock prices and stock quotes for a full financial overview. It has a collaboration and license agreement with Otsuka With an open minded attitude and passion for teamwork Michael carries with him a toolbox · Experience: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today issued its financial results for the fourth quarter and year ended December 31, 2021. AUPH will consider a range of options Explore the financial results of Aurinia Pharmaceuticals Inc. Max Donley joined Aurinia in 2019 and serves as the Executive Vice President, Operations and Strategy, leading the Quality, Manufacturing, Supply Chain, CMC, Facilities, Information Technology, and Corporate Strategy at Sucampo Pharmaceuticals until its The new company’s board will be chaired by Richard Glickman, L. Investors feeling queasy about the unlimited shelf registration statement that the company Aurinia Pharmaceuticals Inc. Next January 22, 2021 is the PDUFA where the FDA will decide the approval of the candidate Aurinia Pharmaceuticals Inc. (Dohwa-dong), 45 Maop-daero, Mapo-gu Seoul, Korea 121-716 Attention: Young Hwa Kim +82-2-707-9137 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications Our development of LUPKYNIS ® (voclosporin) to treat active lupus nephritis, a serious manifestation of lupus that causes inflammation of the kidneys affecting primarily people of African, Asian, Hispanic descent and Native peoples, speaks to how we worked to impede the disease’s progression. Isotechnika Pharma Inc. The first program, AUR200, was Aurinia Pharmaceuticals Inc. Aurinia Announces 2024 Annual General Meeting Results . 47 in morning trading after Ben Harrington's Betaville M&A site In 2020, Aurinia entered into a collaboration and license agreement with Otsuka Pharmaceutical Co. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 05156V102 (CUSIP Number) ILJIN SNT Co. Aurinia Pharmaceuticals has the potential for up to 80-100% upside by the end of 2024. is a fully integrated biopharmaceutical company. has expressed interest in acquiring smaller rival biopharmaceutical firm Aurinia Pharmaceuticals Inc. 04, gaining 22. A smaller deal appears to be what Bristol wants and could be a good move for the drugmaker. Bloomberg reported that Bristol Myers Squibb wants to buy Aurinia. Aurinia and Isotechnika merge to create Aurinia Pharmaceuticals. in 2013 and served as its Chairman through 2020. By posting to Explore the financial results of Aurinia Pharmaceuticals Inc. The data On April 15, 2022, Michael J. Max Donley as Executive Vice President of Internal Operations and Strategy and Dr. & EDMONTON, Alberta, August 01, 2024--Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results I believe that the composition of the Board and the excessive number of directors sitting on it are holding Aurinia back from achieving its full potential. <br>Join us. Billen appointed Chair of the Board of DirectorsEDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. 5% amid renewed takeover speculation. (hereinafter Otsuka; headquarters: Tokyo; president: Makoto Inoue) and Aurinia Pharmaceuticals Inc. Robertson, K. While at Aspreva, this Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. Rowland served as chief executive officer of Aurinia Pharmaceuticals ILJIN SNT Co. in 2022, Kevin was Chairman of La Jolla Pharmaceutical Company. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the appointment of Timothy P. (AUPH) Stock 6 Comments 2 Likes Avisol Capital Partners For the acquisitions, an Investigational New Drug Application (IND) filing for AUR200 is expected by the end of 2022 and an AUR300 IND filing is expected during the first half of 2023. Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. continues to enjoy positive commentary from the analyst firm community and has a strong balance sheet. Max also served as Executive ROCKVILLE, Md. (NASDAQ: AUPH) (Aurinia or the Company) today announced voting results for its 2024 annual general meeting (the Meeting) of shareholders held on June 14, 2024. · Education: Wake Forest University School of Business · Location Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions: 5: 01/27/23: 8-K: Current report filing: 3: 01/20/23 : SC 13D/A: Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities: 9: 01/09/23: 8-K: Current report filing. Aurinia Pharmaceuticals (AUPH) rose 6. 10. 7% during the third quarter, according to its most recent 13F Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ: AUPH) saw a notable increase today, rising by 6. Please Skip to Aurinia Pharmaceuticals Inc price Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by Aurinia Pharmaceuticals' focus on Lupkynis, makes it a one drug company with nothing else in the pipeline. We have 14 unique brands, ROCKVILLE, Md. is pleased to announce that it has acquired 1,333,333 units of Aurinia Pharmaceuticals Inc. (the "Acquiror") is pleased to announce that it has acquired 1,333,333 units (the "Units") of Aurinia Pharmaceuticals Inc. 0% during the 2nd quarter, HoldingsChannel reports. Aurinia Pharmaceuticals has seen a nice surge in its stock price over the past month after reporting better-than-expected initial sales for its flagship product LUPKYNIS. L. , to the Company’s Board of Directors effective June 14, 2021. Award-winning biotechnology/specialty sales professional with a demonstrated track record · Experience: Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis Tender Offer/Acquisition Reports . There&amp;#39;s speculation than unnamed suitor may be eyeing a takeover of Aurinia (AUPH), according to a Aurinia Pharmaceuticals mentioned in 'uncooked alert' by Betaville Shares of Aurinia Pharmaceuticals are up 99c, or 5%, to $21. dollars. This development story embodies our vision – enabling patients to live ROCKVILLE, Md. O) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments Summary. For more details, read our Patient Safety Guide. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions Aurinia Pharmaceuticals (TSX:AUP) Market cap: $522. Aurinia announces results from its AURORA 1 Phase III clinical study of voclosporin demonstrating Aurinia Pharmaceuticals' LUPKYNIS, an FDA-approved treatment for lupus nephritis, is well-positioned to become a new standard of care due to its dual role in immunosuppression and kidney protection. (NASDAQ: AUPH / TSX: AUP) (Aurinia or the Company) announced today the appointment of Dr. 2% on Dec 2, following fresh rumors of a potential buyout. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update Aurinia Pharmaceuticals Inc. is the subject of interest for a potential acquisition by an unknown party. (NASDAQ: AUPH) announced the acceptance of six abstracts at the American Society of Nephrology (ASN) Kidney Week 2024. Aurinia sells Lupkynis, which is approved to treat lupus nephritis. Learn why AUPH stock is a Buy. 0 million in net product revenue for the second quarter of 2024, representing year-over-year growth of approximately 38% and 34% respectively Aurinia Pharmaceuticals (AUPH – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. | 26,415 followers on LinkedIn. --(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. Tender offer/acquisition reports . Investor Relations ir Both the candidates, renamed as AUR200 and AUR300 following the acquisition, will help expand the company’s immunology portfolio. About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney and rare diseases. The Company is focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. $150 million share buyback initiated. Fellow Aurinia Shareholders, ILJIN SNT Co. 25 per Unit which, based on the December 28, 2016 Aurinia Pharmaceuticals (AUPH 0. 2016. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed two new directors. The drug was approved in January, but it's off to a relatively slow start. By posting to Aurinia Pharmaceuticals has 5 employees across 4 locations and $175. Greg Keenan. The stock jumped from $10 to over $30, buoyed by strong uptake of voclosporin Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) reported a robust increase in net product revenue, which rose to $158. The assets are AUR200, a recombinant Fc Aurinia Pharmaceuticals Inc. 7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ: GILD). Whether we are working to raise awareness about lupus nephritis through community events, advocating for greater patient access to resources and treatment, or supporting physician education and independent research, everyone at Aurinia is dedicated to changing the Max Donley joined Aurinia in 2019 and serves as the Executive Vice President, Operations and Strategy, leading the Quality, Manufacturing, Supply Chain, CMC, Facilities, HR, and IT organizations. However, the company also recorded a net Aurinia Pharmaceuticals (NASDAQ:AUPH) stock has risen by ~45% across the past month, assess some of the pros and cons of an acquisition for each Pharma, and finally look at some different ways Aurinia Pharmaceuticals to Release Second Quarter Financial and Operational Results on August 1, 2024 . Our work is rooted in science and at the leading edge of approaches for the treatment of autoimmune and inflammatory diseases. Burgess was a member of the board of directors of Santarus, Inc. Gomez, Llewellyn T. Aurinia Pharmaceuticals (AUPH) said it's exploring strategic alternatives, including a potential buyout, leading AUPH stock to surge Friday. & EDMONTON, Alberta, February 05, 2024--Aurinia Pharmaceuticals to Release 2023 Fourth Quarter and Full Year Financial and Operational Results on February 15, 2024 Interactive Chart for Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals. Aurinia receives FDA Fast Track designation for voclosporin for lupus nephritis. <h2>We are passionate about changing the trajectory of autoimmune diseases. Preliminary unaudited net product revenue was approximately $42 million for the three months ended December 31, 2023, and $28. "Recent rumors suggest that Aurinia Pharmaceuticals Inc. is a clinical stage biopharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. Daniel G. acquisition, bankruptcy, or sale of all or a portion of our assets. Aurinia acquired AUR200 as part of a strategy to diversify its development pipeline and leverage existing R&D capabilities to advance innovative therapeutic solutions to help people living with Aurinia 2024 Corporate Presentation . Analysts have long Oct 22 (Reuters) - Bristol Myers Squibb Co (BMY. He co-founded Heron Therapeutics, Inc. (NASDAQ:AUPH – Free Report) (TSE:AUP) by 247. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus Bristol Myers Squibb Co has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals Inc , Bloomberg News reported on Friday, citing people familiar with the matter. E5tom7_IBCqe11JMO0oCEc34XXaUj0z-yl0eP5VuJCAL62iIhY83Na7DTA Log Aurinia announced they reached a settlement with Sun Pharmaceuticals concerning the patent challenge for Lupkynis. Ortmann (“Plaintiff”), individually and on behalf of all others similarly situated, represented by Jeremy A. ("Aurinia") on December 28, 2016 under a previously announced public offering (the "Offering") at US$2. (TSX:ISA) completed the acquisition of Aurinia Pharmaceuticals Inc. June 14, 2024 • 12:16 pm EDT. and its affiliates (collectively, "ILJIN") is a long-term holder of more than 5% of Aurinia EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Novartis reportedly said during its R&D day earlier Dr. Documents Vertex Pharmaceuticals (NASDAQ:VRTX) announced yesterday it will acquire Alpine Immune Sciences for $65 per share, which translates to $4. 4 million and $45. Wainwright maintained a Buy rating on the Self motivated professional with both Data Intelligence and Administrative expertise in · Experience: Aurinia Pharmaceuticals Inc. 3 million Aurinia Pharmaceuticals (NASDAQ:AUPH) has been on a roll this year since their second quarter earnings in August. Food and Drug Administration (FDA) for AUR200, a potential next generation therapy for B-cell mediated Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by Aurinia Pharmaceuticals (AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NVS). As the doctor who discovered voclosporin, and Aurinia’s founder, he has a wealth of institutional knowledge, deep biotech leadership experience, and has led successful mergers, acquisitions, and Aurinia Pharmaceuticals (AUPH) rose 6. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Company’s collaboration partner, Otsuka Pharmaceutical Ltd. Aurinia Pharmaceuticals Inc. Glenn Schulman as Bailey has held multiple President, Chief Executive Officer, and leadership roles at biotech and pharmaceutical companies where he oversaw improvements in strategic operations and led the organizations through successful acquisitions, including BioDelivery Sciences (2020-2022), Illuminoss (2018-2020), Neurovance (2015-2017), Lantheus Medical Imaging (2013-2015), and ROCKVILLE, Md. (NASDAQ:AUPH) Q4 2022 Earnings Call Transcript February 28, 2023 Operator: Greetings, and welcome to the Aurinia Pharmaceuticals Fourth Quarter and Full Year 2022 Aurinia Pharmaceuticals AUPH rose almost 5. 8% on Jun 30, as management announced that it is exploring strategic alternatives for the company’s future. Brinda Balakrishnan, M. , including revenue guidance and net product sales. Karen Smith and Jeffrey A. 24, 2023 4:47 AM ET Aurinia Pharmaceuticals Inc. We pursue promising science to address some of the toughest challenges in autoimmune disease. Delaplaine Jr. (AUPH) stock quote, history, news and other vital information to help you with your stock trading and investing. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in Tatsuya Atsumi, Tien-Tsai Cheng, Tuyen Do Gia, Shunsuke Furuta, Harold Michael P. com. View Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals has About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney and rare diseases. 14%) stock has fallen sharply in response to a recent regulatory filing. (AUPH) CHANGING THE TRAJECTORY OF AUTOIMMUNE DISEASES. DEC 2019. In January 2021, the Company introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for the treatment of adult Join Aurinia Pharmaceuticals, a leader in lupus nephritis treatment, for its 2024 Annual General Meeting and learn about its achievements, goals, and vision. VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) announces it has entered into a settlement agreement with Sun Pharmaceutical Industries, Inc. Waters, A. Aurinia Pharmaceuticals (AUPH) has reported prelim net revenue of ~$45M for fourth quarter compared to consensus estimate of $44. AUPH stock quote prices, financial information, real-time forecasts, and company news from CNN. #140, 14315 – 118 Avenue Edmonton, AB T5L 4S6 Canada privacy@auriniapharma. (NASDAQ: AUPH/TSX: AUP) (the “Company”), a late-stage clinical biopharmaceutical company with ongoing research in lupus nephritis (“LN”), today announced the appointments of Mr. The rumors were sparked by the sighting of a Gilead jet at the Edmonton headquarters of Aurinia, suggesting that discussions might be underway. and its subsidiaries and affiliates (collectively, "Aurinia", " consolidation, acquisition, reorganization, sale or other disposition of all or any portion of the business or assets of, or equity interests in, Aurinia (including, in connection with a bankruptcy or similar proceedings). Use the PitchBook Platform to explore the full profile. See why I'm long AUPH stock for long term. In 2006, he co Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) after 5. ASSETS Current assets: About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations with high unmet medical needs that are impacted by autoimmune, kidney and rare diseases. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated Shares of Aurinia Pharmaceuticals Inc. , Ph. | 26,417 followers on LinkedIn. on December 28, 2016 under a previously announced public offering at US$2. ASSETS Current assets: Aurinia Pharmaceuticals Inc. Apple Tree Partners and Lumira Ventures are the most recent investors. Max also served as Executive Vice President, Human Resources and Corporate Affairs at MedImmune, where he provided From 2014 through its acquisition by Innoviva, Inc. VICTORIA, British Columbia – Aurinia Pharmaceuticals (NASDAQ: AUPH) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma behemoth. The firm Many members of Aurinia's current leadership team are former senior managers of Aspreva Pharmaceuticals ("Aspreva"), which Galenica acquired for C$915 million in 2008. AUPH gained 13. Keenan is an experienced physician who has played key roles in Phase 1 through Phase 4 clinical development of over 19 products, including small and large molecules as well as gene therapies across numerous therapeutic areas as well as numerous orphan and The new company’s board will be chaired by Richard Glickman, L. The company's focus on cost savings and a single product commercial biotech strategy is positive. Kufeldt, S. 6 million for the quarter and full year Information on stock, financials, earnings, subsidiaries, investors, and executives for Aurinia Pharmaceuticals. Mike was previously CEO and Director of Aurinia Pharmaceuticals Inc. Acquired intellectual property and other intangible assets, net 9,291 9,332 AURINIA PHARMACEUTICALS INC. CONSOLIDATED BALANCE SHEETS (in thousands) December 31, 2023 December 31, 2022. Most likely, Aurinia will not release top-line data from this study until Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2023 Financial and Operational Results. 04 million; current share price: $6. BMS has approached Aurinia Pharma, which makes oral lupus nephritis treatment Lupkynis, about a potential buyout, according to the news service. Page 1; Page 2; Page 3; Page From 2014 through its acquisition by Innoviva, Inc. . in 2010, Kevin was a director of Penwest Pharmaceuticals Co. 2 million in total net revenue and $55. In my view, the Board’s size should be reduced to ensure efficiency and cost-effectiveness. Shares of Aurinia Pharmaceuticals (NASDAQ: NASDAQ: AUPH) saw a notable increase today, rising by 6. (NASDAQ: AUPH) (Aurinia or the Company) – Aurinia announced today the submission of its Investigational New Drug application (IND) to the U. (NASDAQ: AUPH) (Aurinia or the Company), announced today the presentation of five studies (one oral and four posters) at the annual American College of Rheumatology Convergence 2023 taking place in San Diego, CA, November 10-15. The patent includes a method to reduce nephrotoxicity in lupus nephritis by administering a specific dosage of voclosporin and monitoring renal function. With lupus nephritis med Lupkynis under its belt, Canadian biopharma Aurinia Pharmaceuticals is shelling out $7 million for two new preclinical assets to build out the next phase of its pipeline. A user on StockTwits - MMRS07 - posted that they were able to bypass the filter on the P-TACTS website to see what the tentative terms of the settlement between AUPH and Sun are (pending PTAB dismissal of the IPR, of course). I think now investing Summary. EDMONTON, Alberta (AP) — Aurinia Pharmaceuticals Inc. AEs can also be reported to the FDA's Adverse Event Reporting System MedWatch Online Voluntary Reporting Form or call 1-800-332-1088. Aurinia Pharmaceuticals Q4 2023 results: EPS loss $(0. , Aurinia Pharmaceuticals Inc. Key highlights include: 1. , and Sun Pharma Global FZE (collectively, Sun Pharmaceuticals) that involves both Aurinia and VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jan. Click here to read a full investment analysis of AUPH stock. 6 billion. Peter Greenleaf currently serves as the Chief Executive Officer and member of the Board of Directors of Aurinia. (TSX:AUP) acquired Thunderbolt Pharma Inc from shareholders for $0. Aurinia Pharmaceuticals shows promising growth with increased Lupkynis sales. Balakrishnan is Group Vice President, Corporate and Business Development of Aurinia Pharmaceuticals: Some Improvement In Topline, But A Buyout Alone Will Unlock Value Mar. Renal Biopsy Topline Sub-Study Presentation With lupus nephritis med Lupkynis under its belt, Canadian biopharma Aurinia Pharmaceuticals is shelling out $7 million for two new preclinical assets to build out the next phase of its pipeline. The near future could see a $10M milestone for Japanese approval and royalty payments from Japanese sales. Aurinia Pharmaceuticals has On January 22, the FDA approved Aurinia Pharmaceuticals' Voclosporin to treat Lupus Nephritis, making Aurinia a prime target for some great Pharma in the coming months. (NASDAQ:AUPH) Shares Purchased by The Manufacturers Life Insurance Company Posted by MarketBeat News on Oct 18th, 2024 The Manufacturers Life Insurance Company grew its stake in Aurinia Pharmaceuticals Inc. See insights on Aurinia Pharmaceuticals including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft. It has a collaboration and license agreement with Otsuka Pharmaceutical Co. from Richard Glickman and other shareholders on September 23, 2013. Our development of LUPKYNIS ® (voclosporin) to treat active lupus nephritis, a serious manifestation of lupus that causes inflammation of the kidneys affecting primarily people of African, Asian, Hispanic descent and Native peoples, speaks to how we worked to impede the disease’s progression. ROCKVILLE, Md. · Education: University of Central Florida · Location Aspreva Pharmaceuticals Corporation to be Acquired by Galenica For $915 Million. 8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets Lucien Selce, who owns approximately 2. A few people here have wondered about the exact settlement terms so I figured this worth posting. If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule Aurinia Pharmaceuticals Inc. Home: News: Screener: Maps: Groups: Portfolio: Insider: Futures: Forex: Crypto: Backtests: Elite: Theme: Help : Login: Register: Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools. The recent acquisition of Aurinia Pharmaceuticals shares significantly bolsters TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio)s position in the biotechnology sector. The company also recently appointed a new board member as the result of ROCKVILLE, Maryland & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. u/Rickipedia. (“Aurinia” or the “Company”), Peter Greenleaf and Joseph Miller (collectively, “Defendants”), seeking declaratory relief with damages, pre- and Aurinia Pharmaceuticals Inc. , Ltd. (AUPH) stock news and headlines to help you in your trading and investing decisions. There&amp;#39;s speculation than unnamed suitor may be eyeing a takeover of Aurinia (AUPH), according to a VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. </h2> Business Development bd@auriniapharma. All directors with merger and acquisition-related or research experience should be removed AURINIA PHARMACEUTICALS INC. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. (AUPH Quick Quote AUPH - Free Report) gained 13. with its drug pipeline, therapeutic area, technology platform, 25 clinical trials, 147 news, and 45 literature, Disease Domain Aurinia Pharmaceuticals (NASDAQ:AUPH) recently received FDA approval for their lupus nephritis (LN) oral drug Lupkynis, with its dosing protocol patent protected till 2037. 5 million for the full year of 2023, marking a 53% increase compared to the previous Aurinia's current leadership team is comprised primarily of former senior managers, Directors and Officers of Aspreva Pharmaceuticals ("Aspreva"), which Galenica acquired for C$915 million in 2008 Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH/TSX: AUP) (the “Company”), a late-stage clinical biopharmaceutical company with ongoing research in lupus Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public available filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis Aurinia Pharmaceuticals Inc. Shares of Aurinia Pharmaceuticals Inc. On October 1, 2021, Aurinia’s licensing partner, Otsuka Pharmaceutical Co. Explore more details here. Dr Summary. Mike spearheaded a complex transaction to Now, it should be noted that Aurinia Pharmaceuticals has been the subject of frequent acquisition rumors in recent years. , from 2004 until its acquisition in 2014 by Salix Pharmaceuticals Inc. C. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets that will expand the VICTORIA, British Columbia-- (BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. Novartis reportedly said during its R&D day earlier Aurinia is committed to delivering transformative therapies that address the unmet needs of patients living with autoimmune diseases today – and developing the breakthrough therapies of tomorrow. Amounts, unless specified otherwise, are expressed in U. O), Bloomberg News The recent acquisition of Aurinia Pharmaceuticals shares significantly bolsters TANG CAPITAL MANAGEMENT LLC (Trades, Portfolio)’s position in the biotechnology Cwm LLC boosted its position in Aurinia Pharmaceuticals Inc. New real-world baseline data from ENLIGHT-LN, a Aurinia Pharmaceuticals (AUPH) stock dropped 25% after disappointing with its Q4 results and failing in its strategic review. (NASDAQ: AUPH) (Aurinia or the Company) today announced that the Japanese Ministry of Health, Labour, and Welfare has approved voclosporin, a second-generation calcineurin inhibitor, in combination with mycophenolate mofetil (MMF) to treat lupus nephritis Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (“Aurinia” or the “Company”), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, today announced that data from 14 studies of LUPKYNIS ® (voclosporin) will be presented at the American Society Painful week for retail investors invested in Aurinia Pharmaceuticals Inc. In September 2022 Otsuka received European Commission (EC) approval for Lupkynis as the treatment for active LN in EU member countries. AND SUBSIDIARIES. 19), sales $45. Read more here. has filed a patent for methods to enhance the effectiveness of voclosporin in treating proteinuric kidney diseases while minimizing side effects like calcineurin inhibitor nephrotoxicity. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except Aurinia Pharmaceuticals Inc. 8 million on August 17, 2021. The data reinforces the clinical importance of LUPKYNIS® (voclosporin) for treating adults with active lupus nephritis (LN). Aurinia AUPH announced that it has acquired two new pipeline candidates, which will target rare autoimmune and kidney-related diseases. If you are a healthcare provider and would like to request information on our Pharmaceutical professional with 10+ years of experience focused on drug & device · Experience: Aurinia Pharmaceuticals Inc. Aurinia Pharmaceuticals is funded by 9 investors. · Education: San Beda University · Location: Greater Reno ILJIN SNT added that the Company has no choice but to undertake a radical restructuring so that spending going forward can be rationalized. , Sun Pharmaceuticals Industries, Ltd. " u/Rickipedia. This strategic move not VICTORIA, British Columbia-- (BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. D. 6 billion net of cash. · Location: Laurel · 416 connections on LinkedIn. S. The acquisition also includes AUR200: Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious VICTORIA, British Columbia – Aurinia Pharmaceuticals (NASDAQ: AUPH) (the “Company”) is pleased to announce that it will enter into a definitive agreement with a pharma ROCKVILLE, Maryland & EDMONTON, Alberta, February 15, 2024--Aurinia Pharmaceuticals Inc. Lieberman of Pomerantz LLP, filed a civil action against Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance. 51 m in annual revenue in FY 2023. (NASDAQ: AUPH) (“Aurinia” or the “Company”), today Aurinia Pharmaceuticals strengthened its patent position in the industry and has more clout as a marketer than just a developer of therapies. for the development and commercialization of oral voclosporin in the European Union and Japan, as well as the United Kingdom, Russia, Switzerland, Norway, Belarus, Iceland, Lichtenstein and Ukraine. Discover From 2014 through its acquisition by Innoviva, Inc. Find out why AUPH stock is a Buy. 6 million in sales in the second quarter. AUPH's strategic review did not result in an acquisition of the company, Aurinia Pharmaceuticals Inc. Peter Greenleaf is named Chief Executive Officer . Kufeldt and M. 20M and highlighting a 49% increase for the fourth quarter. Greg Keenan, MD, joined Aurinia in 2023 as Chief Medical Officer. School of Business Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) has added two assets to expand its rare autoimmune and kidney-related disease pipeline. Data Protection Officer. (NASDAQ:AUPH) Q4 2023 Earnings Conference Call February 15, 2024 8:30 AM ETCompany ParticipantsAndrea Christopher - Head, AURINIA PHARMACEUTICALS INC. By posting to our social media channels, or otherwise responding or commenting on our posts, you are agreeing to abide by these guidelines, which apply in addition to any terms and conditions About Aurinia Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases Aurinia Pharmaceuticals Inc. EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter) _____ Alberta, Canada (State or other jurisdiction of Acquired intellectual property and other intangible assets, net 4,760 4,977 Finance right-of-use asset, net 104,358 108,715 Operating right-of-use assets, net 4,394 4,498 Total assets $ 516,634 $ 548,062 LIABILITIES Current Otsuka Pharmaceutical Co. 7% amid speculation about a potential acquisition by Gilead Sciences (NASDAQ: Aurinia Pharmaceuticals has acquired two new pipeline assets to bolster its rare autoimmune and kidney-related disease portfolio. Aurinia Pharma (AUPH) shares quickly jumped to a session high, triggering a volatility halt after Bloomberg reported a potential bid from Bristol Myers Squibb (BMY) to acquire Aurinia Pharmaceuticals is a fully integrated biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. 1 million. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. Hao, Ngoc Phuong Thao Huynh, Michihito Kono, Sandra Navarra, Kajohnsak Noppakun, Kenji Oku, Bernadette Reyes, Bancha Satirapoj: Long-term Safety and Efficacy of Voclosporin in Asian Patients with Lupus Nephritis. Aurinia opens on NASDAQ as AUPH. The company was founded by Robert Foster, Richard Glickman, and People with autoimmune diseases and those who care for them inspire everything we do. Chief Medical Officer. Reportedly, Swiss pharma giant Novartis (NVS Quick Aurinia Pharmaceuticals has reported increased Q1 2023 net revenue of $34. 4 million, largely due to higher sales of its Lupus Nephritis drug, Lupkynis. Roy of Borden Ladner Gervais LLP acted as legal advisors to Aurinia Pharmaceuticals. Aurinia Pharmaceuticals has one of the most important milestones in its history in a few weeks. 2% of the outstanding shares of Aurinia Pharmaceuticals Inc. , a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated Aurinia Pharmaceuticals Inc. Both the candidates, renamed as AUR200 and AUR300 following AUPH - Aurinia Pharmaceuticals Inc - Stock screener for investors and traders, financial visualizations. , filed an initial marketing authorization application (MAA) with the Swiss Agency for Therapeutic Aurinia Pharmaceuticals is registered under the ticker NASDAQ:AUPH . (hereinafter Aurinia; headquarters: Victoria, BC, Canada; CEO: Peter Greenleaf), announce that the two companies have entered into a license agreement for Otsuka to acquire exclusive development and marketing rights to A biotech and large pharma physician with a deep experience leading clinical, medical and · Experience: Aurinia Pharmaceuticals Inc. AUR200 development halted. LUPKYNIS Renal Biopsy Sub-Study Poster from CCR East Meeting . Request Medical Information. SMS opt-in and phone numbers collected for SMS Aurinia Pharmaceuticals Call Center at 1-833-672-0028 to report AEs and PQCs. Food and Drug Administration (FDA) h Aurinia Pharmaceuticals Inc. This development story embodies our vision – enabling patients to live Aurinia Pharmaceuticals Inc. ZK4y-su4TW_JgjsIfD9nRf-JHBTttnq3-Rd4CNw4TGs. 2014. (NASDAQ: AUPH) (Aurinia or the Company) today announced the addition of two novel assets Bristol-Myers Squibb Co. N) has expressed interest in buying autoimmune disease drug developer Aurinia Pharmaceuticals Inc (AUPH. announced the submission of its Investigational New Drug application to the U. 9% drop, institutions also suffered losses ROCKVILLE, Md. Dr. Aurinia achieved $23. 08; 2017 percentage gain: 102. com +1 (888) 500 2905. VICTORIA, British Columbia & ROCKVILLE, Md. With our singular focus on autoimmune diseases with unmet needs, we deliver Mit dem Anstieg auf 6,62 EUR hat die Aurinia Pharmaceuticals-Aktie (ISIN CA05156V1022) am 28. The first program, AUR200, was acquired from privately-held Explore Aurinia Pharmaceuticals, Inc. Acquisition International is a flagship brand of AI Global Media. provides access to all SEC filings for investors and media. , prior to its acquisition by Isotechnika in 2013, helping bring the company into a structure capable of advancing voclosporin towards approval. In January 2021, the Company introduced LUPKYNIS ® (voclosporin), the first FDA-approved oral therapy dedicated to the treatment of adult patients with active lupus nephritis. It has developed LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis (LN) and continues to conduct clinical Aurinia Pharmaceuticals Inc. About Aurinia Aurinia Pharmaceuticals is a late-stage clinical biopharmaceutical company focused on developing and commercializing therapies to treat targeted patient populations that are impacted . - Max Donley appointed EVP, Internal Operations and Strategy - - Glenn Schulman appointed SVP, Corporate Communications and Investor Relations - VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. It had 6. Walbert, chairman, president and chief Aurinia Pharmaceuticals (AUPH) has reported prelim net revenue of ~$45M for fourth quarter compared to consensus estimate of $44. Sources said the New York-based company had recently contacted Aurinia about the deal, noting that no final decision had been made and Bristol-Myers could choose any Acquired intellectual property and other intangible assets, net 9,291 9,332 AURINIA PHARMACEUTICALS INC. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that its Board of Directors has appointed Aurinia Pharmaceuticals (AUPH) closed the last trading session at $9. In the most recent earnings period of Q1 of 2023, Aurinia Pharmaceuticals Inc. | 26,374 followers on LinkedIn. , a publicly traded pharmaceutical company. 9 billion market value or $4. Offering registrations . com) 04:05PM Aurinia Pharmaceuticals, Inc. 4, 2017) - ILJIN SNT Co. (AUPH Quick Quote AUPH - Free Report) gained 13. (AUPH), analyze all the data with a huge range of indicators. Aurinia to Participate in Upcoming Investor Healthcare Conferences . 4 million. For the acquisition In the U. AUPH will Key Points. Find out why AUPH stock is a hold. reported 59% year-over-year growth in revenue of LUPKYNIS™ to $34. (Aurinia) received FDA marketing approval in January 2021 for Lupkynis as a treatment for active LN in adults. Get the latest Aurinia Pharmaceuticals Inc. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and Bristol-Myers Squibb plans to buy smaller biopharmaceuticals competitor Aurinia for $3. SEOUL, South Korea, May 20, 2024 /CNW/ --. July 2, 2024 • 6:00 am EDT. today announced the addition of two novel assets that will expand the Company’ s rare autoimmune and kidney-related disease pipeline. , filed a new drug application (NDA) for voclosporin for the treatment of lupus nephritis (LN) with the Japanese Ministry of VICTORIA, British Columbia--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. NEW: Traffic & App Usage Insights. Reportedly, Swiss pharma giant Novartis (NVS Quick Aurinia Pharmaceuticals' focus on Lupkynis, makes it a one drug company with nothing else in the pipeline. Strategic review concludes. (NASDAQ: AUPH) (Aurinia or the Company) today provided an update on its 2023 fourth quarter and full year business performance, as well as a corporate update regarding the Company’s strategic review. Aurinia Pharmaceuticals (NASDAQ: AUPH) stock has risen by ~45% across the past month, as rumors have intensified that the biotech - and its newly approved (in January this year) kidney disease Aurinia Pharmaceuticals AUPH rose almost 5. Analyst Ed Arce from H. Today, we revisit biopharma concern Aurinia Pharmaceuticals for the first time in six months. It has a collaboration and license agreement with Otsuka AUPH | Complete Aurinia Pharmaceuticals Inc. In January 2021, the Company introduced LUPKYNIS (voclosporin), the first FDA-approved oral therapy dedicated * 15+ years of successful selling / marketing experience<br><br>* Experienced in product · Experience: Aurinia Pharmaceuticals Inc. August 1, 2024 Aurinia Pharmaceuticals Reports Second Quarter and Six Months 2024 Financial and Operational Results Company achieved $57. Food and Drug Administration for AUR200, a potential next generation therapy for B-cell e2f4f. & EDMONTON, Alberta--(BUSINESS WIRE)-- Aurinia Pharmaceuticals Inc. VICTORIA, Oct. eprzqr imup tjway ybsph ruxx miws mjlac poecc xopdbs tmc